TCGA-QK-A6IF-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.900 |
| 2 | SRR934972 | — | — | 0.885 |
| 3 | TCGA-BB-4223-01A-01R-1436-07 | — | — | 0.874 |
| 4 | MNG83 | — | — | 0.873 |
| 5 | SRR934810 | — | — | 0.870 |
| 6 | SRR934771 | — | — | 0.867 |
| 7 | MNG1226 | — | — | 0.867 |
| 8 | SRR934905 | — | — | 0.867 |
| 9 | SRR1485789 | GTEX | — | 0.866 |
| 10 | TCGA-CN-5374-01A-01R-1436-07 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |